KinoPharma

Antiviral Company

Developing safe topical treatment for cervical intraepithelial neoplasia (CIN),
human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer.

  • All
  • Press Release
  • Announcement

2021/07/05Announcement

KinoPharma is pleased to announce that it has decided to initiate the highest dose administration in a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer) based on the recommendation of the Data Monitoring Committee.

2021/01/13Announcement

Partnership with IWAKI SEIYAKU CO., LTD.

KinoPharma is delighted to announce that we have entered into a partnership with IWAKI SEIYAKU CO., LTD. for the development of drug formulations in the treatment of verruca and the supply of APIs. In conjunction with the partnership, IWAKI SEIYAKU has purchased new shares of the KinoPharma's stock through a private placement.

Along with its parent company IWAKI & CO., LTD., IWAKI SEIYAKU is engaged in the pharmaceutical and fine chemical businesses from research and development to manufacturing and sales of pharmaceuticals in order to contribute to human health and the pharmaceutical industry. In the pharmaceutical business, IWAKI SEIYAKU distinctively provides solutions in the field of dermatological diseases, through the global collaboration with pharmaceutical companies in the development and manufacture of topical products as well as through the manufacturing and sales of their dermatological product line.

KinoPharma is developing a new concept of antiviral drugs that target host factors to inhibit viral replication. The lead program is in Phase I/II for the treatment of cervical intraepithelial neoplasia (CIN) which is human papillomavirus (HPV) infection causing cervical cancer. KinoPharma is also developing therapeutic agents for various diseases caused by HPV infection, such as verruca vulgaris and condyloma acuminatum.

The partnership is expected to strengthen the supply system of APIs for antiviral drugs and accelerate the development of anti-HPV drugs in the field of dermatology, which will lead to further development and growth of KinoPharma.

2020/10/05Announcement

KinoPharma is delighted to announce the enrollment of the first patient in a multiple-ascending-dose study in the Phase I/II clinical trial for cervical dysplasia (CIN, a precursor to cervical cancer).

2020/07/06Press Release

Kinopharma is delighted to announce the registration of the first subject in phase 1/2 clinical studies in Korea evaluating the safety and efficacy of the anti-HPV agent, Kinopharma’s flagship program, in patients with cervical intraepithelial neoplasia (CIN).

Cervical intraepithelial neoplasia (CIN) is human papillomavirus (HPV) infection of the cervix that could potentially lead to cervical cancer. Currently, there are no approved antiviral drugs for the treatment of CIN. Our clinical candidate anti-HPV agent is intended to treat CIN by removing any types of HPV from the cervix. We aim for the fastest approval of the anti-HPV agent.

2020/01/14Press Release

ASKA Pharmaceutical and KinoPharma Entered into Option Agreement for Treatment of Cervical Dysplasia.

View the press release (PDF)

2018/08/29Press Release

We launched a collaborative research project for exploring new drug development for alzheimer’s disease with National Institutes for Quantum and Radiological Science and Technology.

View the press release (PDF)

2021/07/05Announcement

KinoPharma is pleased to announce that it has decided to initiate the highest dose administration in a multiple-dose clinical trial in patients for cervical dysplasia (CIN, a precursor to cervical cancer) based on the recommendation of the Data Monitoring Committee.

2021/01/13Announcement

Partnership with IWAKI SEIYAKU CO., LTD.

KinoPharma is delighted to announce that we have entered into a partnership with IWAKI SEIYAKU CO., LTD. for the development of drug formulations in the treatment of verruca and the supply of APIs. In conjunction with the partnership, IWAKI SEIYAKU has purchased new shares of the KinoPharma's stock through a private placement.

Along with its parent company IWAKI & CO., LTD., IWAKI SEIYAKU is engaged in the pharmaceutical and fine chemical businesses from research and development to manufacturing and sales of pharmaceuticals in order to contribute to human health and the pharmaceutical industry. In the pharmaceutical business, IWAKI SEIYAKU distinctively provides solutions in the field of dermatological diseases, through the global collaboration with pharmaceutical companies in the development and manufacture of topical products as well as through the manufacturing and sales of their dermatological product line.

KinoPharma is developing a new concept of antiviral drugs that target host factors to inhibit viral replication. The lead program is in Phase I/II for the treatment of cervical intraepithelial neoplasia (CIN) which is human papillomavirus (HPV) infection causing cervical cancer. KinoPharma is also developing therapeutic agents for various diseases caused by HPV infection, such as verruca vulgaris and condyloma acuminatum.

The partnership is expected to strengthen the supply system of APIs for antiviral drugs and accelerate the development of anti-HPV drugs in the field of dermatology, which will lead to further development and growth of KinoPharma.

2020/10/05Announcement

KinoPharma is delighted to announce the enrollment of the first patient in a multiple-ascending-dose study in the Phase I/II clinical trial for cervical dysplasia (CIN, a precursor to cervical cancer).

About KinoPharma

KinoPharma is a clinical stage biopharma to research and develop small-molecule drugs based on new concept in areas of high medical need, such as antiviral drugs, and provide them to patients around the world who are waiting for them as quickly as possible.

Business

Cervical cancer is caused by human papillomavirus (HPV) infection, which not only kills many women, but also causes the loss of the uterus through surgery. We are committed to developing drugs that can treat this disease before it develops.

Research and Development

We take a different approach to discovering and developing next generation antiviral drugs from previous antiviral strategies.